Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice.

Antimicrobial Agents and Chemotherapy
Bohumil SakMartin Kváč

Abstract

Of four genotypes of Encephalitozoon cuniculi, E. cuniculi genotype II is considered to represent a parasite that occurs in many host species in a latent asymptomatic form, whereas E. cuniculi genotype III seems to be more aggressive, and infections caused by this strain can lead to the death of even immunocompetent hosts. Although albendazole has been considered suitable for treatment of Encephalitozoon species, its failure in control of E. cuniculi genotype III infection has been reported. This study determined the effect of a 100× recommended daily dose of albendazole on an Encephalitozoon cuniculi genotype III course of infection in immunocompetent and immunodeficient mice and compared the results with those from experiments performed with a lower dose of albendazole and E. cuniculi genotype II. The administration of the regular dose of abendazole during the acute phase of infection reduced the number of affected organs in all strains of mice and absolute counts of spores in screened organs. However, the effect on genotype III was minor. Surprisingly, no substantial effect was recorded after the use of a 100× dose of albendazole, with larger reductions seen only in the number of affected organs and absolute counts of spores...Continue Reading

References

Oct 24, 1969·Science·J A Shadduck
Sep 1, 1994·Antimicrobial Agents and Chemotherapy·S K KatiyarT D Edlind
Oct 1, 1994·Clinical Microbiology Reviews·R WeberR L Owen
Nov 1, 1993·Journal of Comparative Pathology·R J Chiodini, C D Buergelt
Jun 1, 1996·Tropical Medicine & International Health : TM & IH·S Katzwinkel-WladarschH Rinder
Jul 1, 1997·Antimicrobial Agents and Chemotherapy·E S Didier
Aug 1, 1997·American Journal of Ophthalmology·D C GritzT P Margolis
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Sylvia F. Costa, Louis M. Weiss
Nov 1, 2002·Journal of Clinical Microbiology·D M WolkJ E Rosenblatt
Nov 30, 2004·Veterinary Parasitology·E S DidierP J Didier
Jun 16, 2005·Expert Review of Anti-infective Therapy·Elizabeth S DidierPeter J Didier
Feb 16, 2007·The Journal of Eukaryotic Microbiology·Donna E AkiyoshiSaul Tzipori
May 5, 2007·The American Journal of Cardiology·Franz H MesserliWilliam R Welch
Dec 7, 2007·Antimicrobial Agents and Chemotherapy·Caspar Franzen, Bernd Salzberger
May 23, 2008·Parasitology International·Shajahan JohnyUNKNOWN Bridge study group
Jun 30, 1922·The Journal of Experimental Medicine·J H Wright, E M Craighead
Nov 18, 2009·Cell Host & Microbe·Jianfeng DaiErol Fikrig
May 14, 2010·Journal of Clinical Microbiology·Hana TalabaniJean Menotti
Nov 19, 2011·HIV/AIDS : Research and Palliative Care·Jo Seddon, Sanjay Bhagani
Dec 17, 2011·Comparative Immunology, Microbiology and Infectious Diseases·Alexandra Valencakova, Monika Halanova
Apr 25, 2013·Antimicrobial Agents and Chemotherapy·Maria Anete LalloJoão Manoel de Castro
Apr 15, 2014·Annals of Internal Medicine·Susan N HocevarUNKNOWN Microsporidia Transplant Transmission Investigation Team
Jul 31, 2014·Veterinary Parasitology·Lada HofmannováMartin Kváč
Jan 20, 2016·Journal of Diabetes Research·Dina Silke Malling DamlundHanne Frøkiær
Feb 2, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M KiciaM Kváč
Aug 7, 2017·Experimental Parasitology·Bohumil SakIvona Foitová

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Berliner und Münchener tierärztliche Wochenschrift
W ScharmannW Griem
© 2021 Meta ULC. All rights reserved